Published in Chem Res Toxicol on August 01, 2006
Minireview: the case for obesogens. Mol Endocrinol (2009) 1.33
Circulating levels of phthalate metabolites are associated with prevalent diabetes in the elderly. Diabetes Care (2012) 1.20
The structural basis of pregnane X receptor binding promiscuity. Biochemistry (2009) 1.09
Virtual Screening as a Technique for PPAR Modulator Discovery. PPAR Res (2009) 0.88
Pulmonary phthalate exposure and asthma - is PPAR a plausible mechanistic link? EXCLI J (2013) 0.76
Mediating Roles of PPARs in the Effects of Environmental Chemicals on Sex Steroids. PPAR Res (2017) 0.75
CAPRI: a Critical Assessment of PRedicted Interactions. Proteins (2003) 6.36
ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics (2004) 6.04
PIPER: an FFT-based protein docking program with pairwise potentials. Proteins (2006) 4.31
ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res (2004) 4.10
Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics (2009) 3.00
Anchor residues in protein-protein interactions. Proc Natl Acad Sci U S A (2004) 2.35
Achieving reliability and high accuracy in automated protein docking: ClusPro, PIPER, SDU, and stability analysis in CAPRI rounds 13-19. Proteins (2010) 2.32
Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci (2003) 2.20
Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. Mol Endocrinol (2006) 2.17
Outcome of a workshop on applications of protein models in biomedical research. Structure (2009) 2.05
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 1.96
Structural conservation of druggable hot spots in protein-protein interfaces. Proc Natl Acad Sci U S A (2011) 1.95
Accelerating and focusing protein-protein docking correlations using multi-dimensional rotational FFT generating functions. Bioinformatics (2008) 1.93
MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets. Genome Biol (2012) 1.88
How good is automated protein docking? Proteins (2013) 1.80
Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble. Chem Biol Drug Des (2008) 1.69
Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. J Med Chem (2007) 1.63
Optimal clustering for detecting near-native conformations in protein docking. Biophys J (2005) 1.59
Computational mapping identifies the binding sites of organic solvents on proteins. Proc Natl Acad Sci U S A (2002) 1.56
CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling. J Biol Chem (2003) 1.51
DARS (Decoys As the Reference State) potentials for protein-protein docking. Biophys J (2008) 1.50
Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4alpha-deficient mice. Mol Endocrinol (2004) 1.46
ClusPro: performance in CAPRI rounds 6-11 and the new server. Proteins (2007) 1.46
Unbiased, genome-wide in vivo mapping of transcriptional regulatory elements reveals sex differences in chromatin structure associated with sex-specific liver gene expression. Mol Cell Biol (2010) 1.45
Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus. Endocrinology (2007) 1.39
Identification of substrate binding sites in enzymes by computational solvent mapping. J Mol Biol (2003) 1.37
Protein docking by the underestimation of free energy funnels in the space of encounter complexes. PLoS Comput Biol (2008) 1.36
Dynamic, sex-differential STAT5 and BCL6 binding to sex-biased, growth hormone-regulated genes in adult mouse liver. Mol Cell Biol (2011) 1.36
Liver-specific hepatocyte nuclear factor-4alpha deficiency: greater impact on gene expression in male than in female mouse liver. Mol Endocrinol (2008) 1.30
Sexual dimorphism of rat liver gene expression: regulatory role of growth hormone revealed by deoxyribonucleic Acid microarray analysis. Mol Endocrinol (2003) 1.30
Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A (2010) 1.30
Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase. J Comput Aided Mol Des (2009) 1.30
Codependence of growth hormone-responsive, sexually dimorphic hepatic gene expression on signal transducer and activator of transcription 5b and hepatic nuclear factor 4alpha. Mol Endocrinol (2005) 1.29
Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450. Growth Factors (2004) 1.29
Discrimination of near-native structures in protein-protein docking by testing the stability of local minima. Proteins (2008) 1.27
FTSite: high accuracy detection of ligand binding sites on unbound protein structures. Bioinformatics (2011) 1.25
Protein-protein association kinetics and protein docking. Curr Opin Struct Biol (2002) 1.24
Analysis of binding site hot spots on the surface of Ras GTPase. J Mol Biol (2011) 1.22
SDU: A Semidefinite Programming-Based Underestimation Method for Stochastic Global Optimization in Protein Docking. IEEE Trans Automat Contr (2007) 1.22
Role of STAT5a in regulation of sex-specific gene expression in female but not male mouse liver revealed by microarray analysis. Physiol Genomics (2007) 1.20
Community-wide evaluation of methods for predicting the effect of mutations on protein-protein interactions. Proteins (2013) 1.20
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther (2008) 1.19
Engineered single-chain dimeric streptavidins with an unexpected strong preference for biotin-4-fluorescein. Proc Natl Acad Sci U S A (2005) 1.14
Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery. J Chem Inf Model (2011) 1.13
Rigid Body Energy Minimization on Manifolds for Molecular Docking. J Chem Theory Comput (2012) 1.13
Male-specific hepatic Bcl6: growth hormone-induced block of transcription elongation in females and binding to target genes inversely coordinated with STAT5. Mol Endocrinol (2009) 1.12
Ligand binding and activation of PPARγ by Firemaster® 550: effects on adipogenesis and osteogenesis in vitro. Environ Health Perspect (2014) 1.12
The structural basis of pregnane X receptor binding promiscuity. Biochemistry (2009) 1.09
Dynamic in vivo binding of STAT5 to growth hormone-regulated genes in intact rat liver. Sex-specific binding at low- but not high-affinity STAT5 sites. Mol Endocrinol (2009) 1.09
Application of asymmetric statistical potentials to antibody-protein docking. Bioinformatics (2012) 1.08
Sex-specific early growth hormone response genes in rat liver. Mol Endocrinol (2008) 1.08
Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b. Toxicol Appl Pharmacol (2004) 1.08
Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide. J Biol Chem (2005) 1.06
Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev (2006) 1.06
Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. J Pharmacol Exp Ther (2005) 1.06
Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease. PLoS One (2011) 1.06
VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res (2012) 1.05
Binding hot spots and amantadine orientation in the influenza a virus M2 proton channel. Biophys J (2009) 1.05
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol Cancer Ther (2006) 1.05
Intrinsic sex differences in the early growth hormone responsiveness of sex-specific genes in mouse liver. Mol Endocrinol (2010) 1.05
Combination of scoring functions improves discrimination in protein-protein docking. Proteins (2003) 1.04
Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol (2004) 1.04
Ribosomal protein-sequence block structure suggests complex prokaryotic evolution with implications for the origin of eukaryotes. Mol Phylogenet Evol (2004) 1.03
Genome-wide analysis of chromatin states reveals distinct mechanisms of sex-dependent gene regulation in male and female mouse liver. Mol Cell Biol (2013) 1.03
Minimal ensembles of side chain conformers for modeling protein-protein interactions. Proteins (2011) 1.03
Characterization of three growth hormone-responsive transcription factors preferentially expressed in adult female liver. Endocrinology (2007) 1.03
Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. Biochemistry (2005) 1.02
Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res (2009) 1.01
Role of the cytokine-induced SH2 domain-containing protein CIS in growth hormone receptor internalization. J Biol Chem (2005) 1.01
trans-activation of PPARalpha and induction of PPARalpha target genes by perfluorooctane-based chemicals. Toxicol Sci (2004) 1.00
FTMAP: extended protein mapping with user-selected probe molecules. Nucleic Acids Res (2012) 1.00
A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition. J Pharmacol Exp Ther (2007) 0.99
Sex-specific mouse liver gene expression: genome-wide analysis of developmental changes from pre-pubertal period to young adulthood. Biol Sex Differ (2012) 0.98
Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets (2007) 0.98
PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol Cancer (2010) 0.97
Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Mol Cancer Ther (2007) 0.97
Algorithms for computational solvent mapping of proteins. Proteins (2003) 0.97
Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res (2004) 0.96
Ensemble modeling of substrate binding to cytochromes P450: analysis of catalytic differences between CYP1A orthologs. Biochemistry (2007) 0.96
Aryl hydrocarbon receptor-independent activation of estrogen receptor-dependent transcription by 3-methylcholanthrene. Toxicol Appl Pharmacol (2005) 0.96
Antiangiogenesis enhances intratumoral drug retention. Cancer Res (2011) 0.95
Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis (2006) 0.95
Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces. J Chem Inf Model (2012) 0.95
Where does amantadine bind to the influenza virus M2 proton channel? Trends Biochem Sci (2010) 0.94
Role of hepatocyte nuclear factors in transcriptional regulation of male-specific CYP2A2. J Biol Chem (2004) 0.93
Interactions of methoxyacetic acid with androgen receptor. Toxicol Appl Pharmacol (2008) 0.93
Environmental phthalate monoesters activate pregnane X receptor-mediated transcription. Toxicol Appl Pharmacol (2004) 0.92
Performance of the first protein docking server ClusPro in CAPRI rounds 3-5. Proteins (2005) 0.92
Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J Virol (2011) 0.91
Impact of CUX2 on the female mouse liver transcriptome: activation of female-biased genes and repression of male-biased genes. Mol Cell Biol (2012) 0.91
Comprehensive experimental and computational analysis of binding energy hot spots at the NF-κB essential modulator/IKKβ protein-protein interface. J Am Chem Soc (2013) 0.91
Blind prediction of interfacial water positions in CAPRI. Proteins (2013) 0.90
Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol In Vitro (2005) 0.90
Signalling cross-talk between hepatocyte nuclear factor 4alpha and growth-hormone-activated STAT5b. Biochem J (2006) 0.90
Insights into the architecture of the eIF2Bα/β/δ regulatory subcomplex. Biochemistry (2014) 0.90
Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab Dispos (2005) 0.90
Domain motion and interdomain hot spots in a multidomain enzyme. Protein Sci (2010) 0.89